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As outlined in the May 2018 publication American Patients First: The Trump Administration 
Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, high drug list prices are 
considered a major affordability challenge for the United States healthcare system. In the 
blueprint, the Department of Health & Human Services (HHS) identified that there should be 
incentives to lower list prices. Thus far, strategies pursued by the Food and Drug Administration 
(FDA) include evaluating the implications of requiring manufacturers to include list prices in 
advertising, and consideration for updating Medicare’s drug-pricing dashboard to make price 
increases and generic competition more transparent.1 
Incentives or regulatory changes could restrict the use of rebates and thus reduce the effect of 
rebates on list prices. The blueprint provides a recommendation to remove a cap on rebates on 
drugs in the Medicaid program, which could impact list prices and price increases.1 
The Medicaid Drug Rebate Program offsets the Federal and state costs of most outpatient 
prescription drugs dispensed to Medicaid patients.2 Approximately 600 manufacturers participate 
in this program.2 The blueprint makes the argument that rebates for federal drug programs may 
have caused subsequent higher list prices for drugs since drug manufacturers would raise list 
prices to maintain profit margins and offer larger rebates.1 
Given the complexities of the drug distribution chain and payment system, any attempt to lower 
list prices by eliminating drug rebates could have widespread implications for payers, pharmacy 
benefit managers (PBMs), and ultimately, patients. List prices currently do not reflect rebates 
and concessions paid to health plans or government programs.1 
One aspect that could have the most impact on the healthcare system outlined in the blueprint is 
eliminating rebates, which are cost-savings measures that PBMs often use to leverage formulary 
placement. 
In July 2018, the Trump Administration proposed a rule that would scale back protections that 
allow for rebates between drug manufacturers and PBMs. Although specifics of this rule were 
unclear, this is an indication that the legal status of these types of rebates are being reviewed, as 
they are implicated as a cost-driver of list prices. This move has caused both drug manufacturers 
and PBMs to go on the offensive, with drug manufacturers stating they were under pressure to 
keep PBMs at bay while PBMs are stating that their negotiation tactics (such as leveraging 
rebates and formulary placement) have controlled total drug costs.3,4 
Removing rebates is a unique approach to increasing the transparency of list prices, which will 
hopefully lead to lower prices. However, addressing how to remove rebates would take time, 
especially given how rebates are entangled in the Medicaid Drug Rebate Program and formulary 
management strategies of PBMs. A thoughtful approach would be required before any processes 
related to removing rebates can proceed. As a result, in August 2018, members of Congress 
urged the Office of Management and Budget (OMB) to consider the economic impact of the 
proposal that alters the use of rebates between drug manufacturers and PBMs.5 
Until further economic analyses are done on the impact of rebates, it is unknown how and if the 
Trump Administration will untangle rebates from the intricate drug payment system to lower list 
prices. 
In the New Year, our next blog on drug prices will tackle the issue of out-of-pocket costs. 
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